COVID-19 and HIV infection co-pandemics and their impact: a review of the literature

Sivaporn Gatechompol1,2, Anchalee Avihingsanon1,2, Opass Putcharoen3, Kiat Ruxrungtham4* and Daniel R. Kuritzkes5

Abstract
Coronavirus disease 2019 (COVID-19) was first detected in December 2019. In March 2020, the World Health Organization declared COVID-19 a pandemic. People with underlying medical conditions may be at greater risk of infection and experience complications from COVID-19. COVID-19 has the potential to affect People living with HIV (PLWH) in various ways, including be increased risk of COVID-19 acquisition and interruptions of HIV treatment and care. The purpose of this review article is to evaluate the impact of COVID-19 among PLWH. The contents focus on 4 topics: (1) the pathophysiology and host immune response of people infected with both SARS-CoV-2 and HIV, (2) present the clinical manifestations and treatment outcomes of persons with co-infection, (3) assess the impact of antiretroviral HIV drugs among PLWH infected with COVID-19 and (4) evaluate the impact of the COVID-19 pandemic on HIV services.

Keywords: COVID-19, HIV, Co-infection, Pathophysiology, Clinical, Outcome

Introduction
In December 2019, a cluster of cases of pneumonia was reported in Wuhan, Hubei Province, China. The source of the infection was later identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). On March 11, 2020 the World Health Organization (WHO) declared COVID-19 as a global pandemic [1]. As of 22 March 2021, more than 123 million cases have been confirmed globally along with 2.7 million deaths [2]. Older age and comorbidities such as hypertension, diabetes and cardiovascular disease are risk factors for developing severe COVID-19 and are associated with a high mortality rate [3–5]. However, data are limited on the impact of COVID-19 on people living with HIV (PLWH) who may be considered an immunocompromised population. Globally, there are 38 million PLWH, 690,000 of whom died of HIV-related illnesses in 2019 [6]. The WHO estimated that only 67% of PLWH were on antiretroviral therapy (ART) worldwide in 2019 [7]; only 60% of the people with HIV infection were aware of their HIV status [8]. Therefore, PLWH not on ART or whose disease is not well controlled may be at increased risk for contracting COVID-19 because their immune systems are compromised. Such persons may also be at increased risk for developing serious symptoms and death if infected with COVID-19. Limited information is available, however, regarding the treatment and outcome of SARS-CoV-2 infection among PLWH.

Recently, many countries have reported disruptions in the delivery of HIV services and care due to the COVID-19 pandemic [9]. This disruption may increase the morbidity and mortality among PWLH beyond those infected with COVID-19 [10, 11]. However, the information regarding the impact of COVID-19 on HIV services is scarce.

In this review, we describe the pathophysiology and host immune response of people infected with both SARS-CoV-2 and HIV, present the clinical manifestations and treatment outcomes of persons with co-infection,
assess the impact of antiretroviral HIV drugs among PLWH infected with COVID-19 and evaluate the impact of the COVID-19 pandemic on HIV services.

**Pathophysiology and host immune response to SARS-CoV-2 and HIV infections**

The pathophysiology and immune response of people infected with COVID-19 has been reviewed [12, 13]. In brief, SARS-CoV-2 is a β coronavirus characterized by its four structural proteins: Spike (S), membrane (M), envelop (E) and nucleocapsid (N) [14]. The life cycle of SARS-CoV-2 consists of the following 5 steps: attachment, penetration, biosynthesis, maturation and release [12]. Angiotensin converting enzyme 2 (ACE2) is the receptor for SARS-CoV-2 [15, 16]. Single-cell RNA sequencing has shown that ACE2 is highly expressed in the lung, heart, ileum, kidney and bladder [17]. In addition, the acute loss of smell (anosmia) has been reported in patients with COVID-19 [18]. However, ACE2 was not detected in either olfactory sensory neurons or olfactory bulb neurons [19]. Therefore, infection of non-neuronal cell types may be primary source leads to olfactory dysfunction in patients with COVID-19.

After SARS-CoV-2 infects epithelial cells of the upper respiratory tract, virus produced by infected cells travels to the lower airway, infecting bronchial and alveolar epithelial cells and alveolar macrophages [20]. As a consequence of innate immunity, virus-infected epithelial cells undergo apoptosis and are phagocytized by antigen presenting cells (APC) such as dendritic cells (DCs) and macrophages. The APC migrate to draining lymph nodes to present viral antigens to T cells [12]. Both CD4+ and CD8+ T cells play a major role in fighting against the coronavirus [21]. CD4+ T cells activate B cells to promote the production of virus-specific antibodies, while CD8+ T cells can directly kill virally infected cells [12]. In severe COVID-19, interstitial mononuclear inflammatory infiltrates, dominated by lymphocytes, are seen in lung biopsy [22]. Furthermore, desquamation of pneumocytes and pulmonary oedema with hyaline membrane formation indicating acute respiratory distress syndrome (ARDS) have been reported [22, 23]. A summary of the pathophysiology and clinical manifestations of COVID-19 are shown in Fig. 1.

In contrast, HIV binds to the CD4 receptor of the host cell, followed by engagement of a co-receptor (i.e., chemokine receptor 5 (CCR5) or chemokine receptor 4 (CXCR4)). The characteristics of SARS-CoV-2 are compared to HIV in Table 1. All CD4 positive cells (i.e., T helper cells), macrophages, dendritic cells and astrocytes are susceptible to HIV [24]. Direct viral cytopathic effects of HIV as well as indirect effects including host innate immune response to viral DNA produced during abortive infection and endotoxin/microbial translocation from leaky guts, persistent immune activation, immune dysregulation and CD4 T cell homeostasis failure are keys to the pathogenesis of HIV that leads to CD4 T cell depletion and immune compromise in HIV [25–27]. A summary of the host immune response following exposure to HIV is shown in Fig. 2.

---

**Fig. 1** Pathophysiology and clinical manifestations of COVID-19. Created with BioRender.com
The lymphocyte analysis studies among patients with COVID-19 demonstrate that T lymphopenia—in particular, a decrease in CD4+ T cells—were common among patients with COVID-19, and more evident in severe cases [28, 29]. If superimposed on low CD4 counts in patients with advanced HIV disease, the lymphopenia of COVID-19 could delay the clearance of SARS-CoV-2 and promote disease progression. Moreover, COVID-19–associated pulmonary aspergillosis (CAPA) among severely ill COVID-19 patients has been reported worldwide, raising concerns of an additional contributing factor to mortality [30–32]. The pathological factors that may be associated with CAPA are the damaged respiratory epithelium, dysfunctional mucociliary clearance and low immune response, including low CD4 cell count [33, 34].

Elevated levels of multiple proinflammatory cytokines such as IL-2, IL-6, IL-10, and IFN-γ in severe cases of COVID-19 cannot only promote a hypercoagulable state, but also enhance the pro-thrombotic functions [35].
Moreover, a study reported a pattern of tissue damage consistent with complement-mediated microvascular injury among individuals with severe COVID-19 [36]. High incidence of thrombotic complications has been reported among COVID-19 patients admitted in intensive care unit [37].

HIV infection also is recognized as a prothrombotic condition [38–40]. Hence, COVID-19 and HIV co-infected patients could have a high risk of developing thrombosis. However, further studies are needed to prove this possibility.

Clinical presentation and treatment outcome of COVID-19 among patients with HIV infection

Although several large cohort studies have reported the clinical characteristics and treatment outcome of COVID-19 in the general population [3, 4], clinical outcomes data on COVID-19 among patients with HIV are sparse. In this section, we summarize the demographics, clinical presentation and treatment outcome of COVID-19 among HIV-infected individuals from case series as well as epidemiological and cohort studies (Table 2).

Many studies conducted among PLWH with COVID-19 reported a median age range between 40 and 61 years and majority of them were men, which is similar to that reported in the general population [3, 4]. Most of the PLWH with COVID-19 were on antiretroviral therapy and were virologically suppressed. The incidence rate of COVID-19 infection among PLWH differs by country. The US (0.8%) [3] and Spain (1.8%) [41] reported an incidence of COVID-19 infection among PLWH with COVID-19 were similar to those reported in people without HIV such as older age and comorbid medical conditions [42, 55].

The impact of antiretroviral HIV drugs among patients co-infected with COVID-19

The S protein of the coronavirus mediates viral entry into targeted cells by binding to its receptor, ACE2, which leads eventually to viral fusion with the host cell membrane. However, the S protein is synthesized as an inactive precursor that requires activation by host cell proteases TMPRSS2 or cathepsin B or L to become a fusion active form. Thus, protease inhibitors have been considered as a candidate therapy for SARS-CoV and other coronaviruses [57, 58]. Treatment with the HIV protease inhibitor with lopinavir/ritonavir (LPV/r) showed some benefit in a non-human primate model of MERS-CoV infection [59]. Recent in vitro studies reported that antiviral activity of LPV/r against SARS-CoV-2, albeit at a relatively high EC50 [60, 61]. However, several observational studies and case reports demonstrated that the clinical benefit of using LPV/r among COVID-19 patients was inconclusive [62–65]. Moreover, a randomized, controlled open-label trial conducted in hospitalized adult patients with severe COVID-19 failed to show a statistically significant difference in time to clinical improvement or mortality in the LPV/r-treated group as compared to standard of care [66]. Moreover, LPV/r treatment was stopped early in 13 patients (13.8%) because of adverse events. The lack of clinical benefit of LPV/r for COVID-19 was confirmed in the RECOVERY and SOLIDARITY trials [67, 68].

In vitro data show the absence of any anti-SARS-CoV-2 activity of darunavir [69]. This finding is corroborated by the clinical observation that PLWH receiving a darunavir-containing regimen were not protected from COVID-19 [70].

Antiviral activity of tenofovir against SARS-CoV-2 has been demonstrated in virtual and in vitro studies [71, 72]. These results led to speculation that tenofovir disoproxil fumarate (TDF)– and tenofovir alafenamide (TAF)–containing antiretroviral regimens might have a protective
Table 2  Summarization of HIV-infected individuals’ demographic data, clinical presentation and treatment outcome of COVID-19

| No. of patients | Country | Median age (-years, median, IQR) | Male, n (%) | Comorbidities, n (%) | HIV clinical characteristics | COVID-19 clinical presentations |
|-----------------|---------|----------------------------------|-------------|----------------------|-----------------------------|--------------------------------|
|                 |         |                                  |             |                      |                             |                                |
| 93              | USA, New York | 58 (52–65) | 67 (72%) | 49 (53%) | 20 (15–26) | Fever 61 (66%) |
| 88              | USA, New York | 61 (54–67) | 66 (75%) | 32 (34%) | 554 (339–752) | Cough 66 (81%) |
| 51              | Spain    | 53 (Mean; range 31–75) | 43 (84%) | 16 (17%) | NA | NA |
| 47              | Italy    | 51 ± 12 (Mean ± SD) | 36 (76%) | 18 (35%) | NA | NA |
| 36              | USA, Boston | 53 (Mean; range 24–81) | 21 (58%) | 14 (30%) | NA | NA |
| 31              | USA, New York | 60.7 (Mean; range 23–89) | 24 (77%) | 11 (31%) | NA | NA |
| 27              | USA, Rhode Island | 51 (40.5–57) | 21 (78%) | 6 (22%) | NA | NA |
| 27              | USA, New Jersey | 58 (50–67) | 15 (55%) | 16 (59%) | NA | NA |
| 18              | United Kingdom | 52 (49–58) | 12 (67%) | 6 (33%) | NA | NA |
| 9               | USA, New York | 58 (52–70) | 7 (78%) | 5 (56%) | NA | NA |
| 9               | China, Wuhan | 57 (48–62) | 7 (88%) | NA | NA | NA |
| 8               | USA, New York | 55 (50–67) | 8 (100%) | 5 (50%) | NA | NA |

**HIV clinical characteristics**
- **Time since HIV diagnosis, years, (median, IQR):**
  - 20 (15–26)
- **Preadmission CD4 count, cells/μL (median, IQR):**
  - 554 (339–752)
- **Preadmission HIV RNA < 200 copies/mL, n (%):**
  - 57 (84%)

**COVID-19 clinical presentations**
- **Time since onset of COVID-19 symptoms to admission or diagnosis, Days, median (IQR):**
  - NA
- **Presenting symptoms, n (%):**
  - Fever 61 (66%)
  - Cough 71 (76%)
COVID-19: coronavirus disease 2019; HIV: human immunodeficiency viruses; ART: antiretroviral therapy; PI: Protease inhibitor; INSTI: Integrase inhibitors; NNRTI: Non-nucleoside reverse transcriptase inhibitor; NRTI: Nucleoside reverse transcriptase inhibitor

All of the patients in the studies that were shown in the Table 2 presented with symptoms of COVID-19

Table 2 (continued)

| Study                          | Hsi-en Ho et al. [43] | Sigel et al. [49] | Vizcarra et al. [41] | Gervasoni et al. [54] | Meyerowitz et al. [45] | Shalev et al. [45] | Byrd et al. [52] | Okoh et al. [44] | Childs et al. [53] | Suwanwongse et al. [46] | Guo et al. [42] |
|-------------------------------|-----------------------|-------------------|----------------------|------------------------|------------------------|-------------------|-------------------|-------------------|-------------------|------------------------|------------------|
| Shortness of breath or dyspnea | 57 (61%)              | NA                | 28 (55%)             | 10                     | 14 (39%)               | NA                | 9 (53%)           | 17 (63%)          | 12 (67%)          | 6 (67%)               | NA               |
| Infiltrates on radiograph, n (%) | 71 (79%)f             | NA                | NA                   | 12 (25%)f              | NA                    | 20 (65%)          | 13 (48%)f         | NA                | 13 (72%)          | 8 (89%)               | NA               |
| Needed Mechanical ventilation, n (%) | 15 (21%)              | 21 (10%)i         | 5 (10%)              | 2 (4%)                 | 7 (19%)               | 8 (26%)           | NA                | NA                | 5 (28%)           | 5 (56%)               | NA               |
| COVID severity, n (%)          | Most mild to moderate | Most mild to moderate | Mild or moderate: 38 (75%), Severe: 13 (25%) | Most mild to moderate | Most severe: 13 (39%), Moderate: 69 (61%) | Most mild to moderate | Most mild to moderate | Most mild to moderate | Most severe | Most mild to moderate |
| Outcome of COVID-19, n (%)     | 53 (74%)g             | 70 (79%)f         | 44 (86%)             | 45 (96%)               | 30 (89%)              | 21 (68%)          | 26 (96%)          | 25 (85%)         | 12 (67%)          | 2 (22%)               | NA               |
| Cure or discharge              | 0 (%)                 | 18 (21%)          | 2 (4%)               | 2 (4%)                 | 8 (26%)              | 1 (4%)            | 2 (15%)           | 5 (28%)           | 7 (78%)           | 1 (12.5%)             | NA               |
| Hospitalized                   |                       |                   |                      |                        |                      |                   |                   |                   |                   |                       |                  |
| Died                           | 19 (26%)f             | 18 (21%)          | 2 (4%)               | 2 (4%)                 | 2 (6%)               | 8 (26%)           | 1 (4%)            | 2 (15%)          | 5 (28%)           | 7 (78%)               | 1 (12.5%)         |

COVID-19: coronavirus disease 2019; HIV: human immunodeficiency viruses; ART: antiretroviral therapy; PI: Protease inhibitor; INSTI: Integrase inhibitors; NNRTI: Non-nucleoside reverse transcriptase inhibitor; NRTI: Nucleoside reverse transcriptase inhibitor

All of the patients in the studies that were shown in the Table 2 presented with symptoms of COVID-19

d Data available for analysis n = 19
e Data available for analysis n = 17
f Chest Computed Tomography-confirmed pneumonia
g Data available for analysis n = 57
h Data available for analysis n = 64
i Data available for analysis n = 68
j Data available for analysis n = 90
k Outcome in those hospitalized n = 72
l Viral load < 120 copies/ml
m HIV RNA level at admission
n HIV RNA level at admission or within previous 12 months (N = 82)
o Only percentage was reported
p Combined between discharge and still hospitalized
q Data available for analysis n = 8
effect against COVID-19 [3]. However, a prospective cohort in Spain observed a higher rate of COVID-19 infection among PLWH on TAF or TDF [41]. This finding supports the results from case series that tenofovir-based ART does not provide any clinical benefit against COVID-19 among PLWH [45, 52]. Therefore, up until now, the use of antiretroviral agents has no clinical benefit for the treatment or prevention of COVID-19.

### HIV service during COVID-19 outbreak

COVID-19 pandemic has had an unprecedented negative impact on HIV services and care across the globe. According to a WHO report, between April and June 2020 73 countries faced the risk of ART disruption affecting 17.7 million people receiving ART [9]. A modelling study done by WHO and UNAIDS estimated that a 6-month disruption of ART could lead to more than 500,000 extra deaths from AIDS-related illnesses in sub-Saharan Africa in 2020–2021 [73].

Several factors have contributed to the disruptions in HIV service and care during the COVID-19 pandemic. First, the strict quarantine measures and transportation lock downs were implemented in many cities to control the spread of COVID-19. A survey from China reported that PLWH who returned to their home towns could not refill their medication due to the lock down [74]. Not surprisingly, the shortage of ART affected not only the physical health status of PLWH but also caused considerable psychological stress. Postal delivery of drugs is one approach to ensure that PLWH have a continuous supply of ARVs. However, this method poses implementation challenges because not all PLWH want ARVs delivered to their homes in order to maintain privacy and guard against unwanted disclosure of their HIV status to household members [75]. Second, there have been shortages of ARV because of shut downs by certain drug manufacturers [9]. Third, healthcare workers who provide care for PLWH were diverted to care for patients with COVID-19 [75–77]. A survey performed in Central and Eastern Europe reported that infectious disease physicians shifted their focus to take care COVID-19 patients instead of PLWH [78].

During this difficult time, healthcare systems must develop effective strategies for balancing healthcare resources need by both PLWH and patients with COVID-19. ARV multi month dispensing (MMD) policy has been adopted in many countries [9] in order to prevent disruptions of ARV supplies for PLWH and to reduce their exposure to COVID-19 when accessing HIV services. Telemedicine platforms have been proposed as a strategy for continued provision of healthcare to PLWH in response to COVID-19 during the lock-down period and have been implemented successfully in many settings [79]. A multidisciplinary approach to help PLWH maintain their physical and mental health has never been more important than now, in the face of the COVID-19 pandemic. In addition, other services for prevention and treatment of opportunistic infection and sexually transmitted infections may be disrupted during COVID-19 pandemic. This lockdown related disruptions may increase in burden of TB and sexually transmitted infections [80–82].

### Conclusion

Even though lymphopenia associated with COVID-19 may further decrease CD4+ T cell counts in PLWH, there are no differences in the clinical presentations, outcomes, morbidity and mortality between individuals who have SARS-CoV-2 with or without HIV infection. Several randomized control trials have shown that antiretroviral therapy has no beneficial effect among people infected with SARS-CoV-2 compared to standard of care.

To date, we still do not have any proven antiviral agents that reduce mortality among COVID-19 patients. Right now, the medical resources have shifted towards COVID-19 but it should be noted that we should not overlook the care for PLWH who still need ART and follow-up care. We should use several innovative service deliveries and MMD policy to help PLWH have continuous supply of ARV during this outbreak.

### Abbreviations

HIV: Human immunodeficiency viruses; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; WHO: World Health Organization; PLWH: People living with HIV; ART: Antiretroviral therapy; ACE2: Angiotensin converting enzyme 2; APC: Antigen presenting cells; DCs: Dendritic cells; ARDS: Acute respiratory distress syndrome; CCR5: Chemokine receptor 5; CXCRA: Chemokine receptor 4; LPV/r: Lopinavir/ritonavir; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir alafenamide; MMD: Multi month dispensing.

### Acknowledgements

We would like to thank the medical staff for taking care of the patients during the outbreak. We would like to thank Pirapon June Ohata for proofreading the manuscript.

### Authors’ contributions

SG performed the literature review, produced the figure, wrote and revised the manuscript. AA, OP edited the manuscript. KR and DK supervised and edited the manuscript. All authors read and approved the final manuscript.

### Funding

No funding was used for the write-up of this review article.

### Availability of data and materials

Not applicable.

### Declarations

Ethics approval and consent to participate

Not applicable.
References

1. WHO. Timeline of WHO’s response to COVID-19. Last updated 30 July 2020. https://www.who.int/news-room/detail/29-06-2020-covid-timeline. Accessed 1 Nov 2020.

2. The Johns Hopkins Coronavirus Resource Center. COVID-19 data. https://coronavirus.jhu.edu. Accessed 6 Nov 2020.

3. Richardson S, Hirsch J, Narasimhan M, Crawford JM, McGinn G, Summit KD, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323:2052–9.

4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.

5. Lithander FE, Neumann S, Tenison E, Lloyd K, Welsh TJ, Rodrigues JCL, et al. COVID-19 in older people: a rapid clinical review. Age Ageing. 2020;49:501–15.

6. WHO. HIV/AIDS data and statistics. https://www.who.int/hiv/data/en/. Accessed 1 Nov 2020.

7. WHO. Estimated Antiretroviral therapy coverage. https://www.who.int/gho/data/viewmain.33000REGION=laom. Accessed 1 Nov 2020.

8. UNAIDS. Global HIV & AIDS statistics—2018 fact sheet. Geneva. UNAIDS. 2018. http://www.unaids.org/en/resources/fact-sheet.

9. WHO. Disruption in HIV, Hepatitis and STI services due to COVID-19. https://www.who.int/docs/default-source/hiv-hq/presentation-disruption-in-services-international-aids-conference-2020.pdf?sfvrsn=d4bf1f87_7. Accessed 1 Nov 2020.

10. El-Sadr WM, Justman J. Africa in the Path of COVID-19. N Engl J Med. 2020;383:e11.

11. Drain PK, Garrett N. SARS-CoV-2 pandemic expanding in sub-Saharan Africa: considerations for COVID-19 in people living with HIV. EJClincalMedicine. 2020;222.

12. Yuki K, Fujogi M, Koutsogianni S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:21.

13. Promptpetcha E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1–9.

14. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77:8801–11.

15. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525:135–40.

16. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–9.

17. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14:185–92.

18. Tong Y, Wong A, Zhu D, Fastenberg JH, Tham T. The prevalence of olfactory and gustatory dysfunction in COVID-19 Patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020;163:3–11.

19. Brann DH, Tsukahara T, Weinreb C, Lipsovsek M, Van den Berge K, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020;6.eabb5801.

20. Yoshikawa T, Hitit T, Li K, Peters CJ, Tseng CT. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of mono- cytode-derived macrophages and dendritic cells. J Virol. 2009;83:3039–48.

21. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59:118–28.

22. Xu H, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.

23. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93.

24. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872–7.

25. Okoye AA, Picker LJ. CD4(-) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. 2013;254:54–64.

26. Doitsh G, Greene WC. Dissecting how CD4 T cells are lost during HIV infection. Cell Host Microbe. 2016;19:280–91.

27. Alzahrani H, Hussain S, Siram D, Palchaudhuri R, Abdel-Mohsen M, Crowe SM, et al. Inflammatory and immunometabolic consequences of gut dysfunction in HIV: parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities. EbioMedicine. 2019;46:522–31.

28. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762–8.

29. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.

30. Koehler P, Comely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63:28–34.

31. Alario A, Dellière S, Fodil S, Bretagne S, Mérigarde B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8:e48–9.

32. Lansbury L, Lim B, Baskaran Y, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81:266–75.

33. Herold S, Becker C, Ridge KM, Budiinger GR. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J. 2015;45:1463.

34. Rutseaet L, Steinfort N, Van HunselT, Romans P, Naensens R, Merets H, et al. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care. 2020;10:71.

35. Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. J Thromb Thrombolysis. 2021;51:313–29.

36. Magno C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Trans Res. 2020;220:1–13.

37. Klok FA, Kruip M, Broekhuizen R, de Vries DJ, Bolder D, Bisseling T, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63:28–34.

38.NSMutableAttributedString. COVID-19: the potential association with severe respiratory disease and gut dysfunction in HIV: parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities. EBioMedicine. 2019;46:522–31.

39. Malek J, Rogers R, Kufera J, Hirshon JM. Venous thromboembolic disease associated with severe illness. J Thromb Thrombolysis. 2021;51:313–29.

40. Klok FA, Kruip M, Broekhuizen R, de Vries DJ, Bolder D, Bisseling T, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63:28–34.

41. Vizcarra P, Pérez-Elías MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63:28–34.

42. Guo W, Ming F, Dong Y, Zhang Q, Zhang X, Mo P, et al. A survey for COVID-19 among HIV/AIDS patients in two districts of Wuhan. SSRN: China; 2020.
43. Ho HE, Peluso MJ, Marquis C, Matias Lopes JP, He C, Gaisa MM, et al. Clinical outcomes and immunological characteristics of COVID-19 in people with HIV. J Infect Dis. 2020;223(3):403–8.

44. Okoh AK, Bishburg E, Grinberg S, Nagarakanti S. COVID-19 pneumo-nia in patients with HIV-a case series. J Acquir Immune Defic Syndr. 2020;85(1):e4–5.

45. Shalene N, Scherer M, LaSota ED, Antoniou P, Yin MT, Zucker J, et al. Clinical characteristics and outcomes in people living with HIV hospitalized for COVID-19. Clin Infect Dis. 2020;71(16):2294–9.

46. Suwanwongse K, Shabarek N. Clinical features and outcome of HIV/ SARS-CoV-2 coinfected patients in The Bronx, New York City. J Med Virol. 2020;92(11):2387–9.

47. Goyal P, Choo JJ, Pinheiro LC, Schenck EJ, Chen R, Jabi A, et al. Clinical characteristics of covid-19 in New York City. N Engl J Med. 2020;382:2372–4.

48. Akelam E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020;382:2475–7.

49. Sigel K, Swartz T, Golden E, Panarik I, Somani S, Richter F, et al. Covid-19 and people with HIV infection: outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020;71(11):2933–8.

50. Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr. 2020;85(6):10–2.

51. Blanco J, Ambrosioni J, Garcia F, Martinez E, Soriano A, Mallosa J, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7:e314–6.

52. Byrd KM, Beckwith CG, Garland JM, Johnson JE, Aung S, Cu-Uvin S, et al. SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States. J Int AIDS Soc. 2020;23.

53. Childs K, Post FA, Norcross C, Ottaway Z, Hamlyn E, Quinn K, et al. Hospitalized patients with COVID-19 and HIV: a case series. Clin Infect Dis. 2020;71(8):1781–7.

54. Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, et al. COVID-19 in congregate settings among a large cohort of people with HIV. AIDS. 2020;34(12):2021–2.

55. Guo W, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir- ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382:1787–99.

56. Horby PW, Ma Vi H, Bell JL, Linsell S, Staplin N, Emberson J, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10251):1354–52.

57. Pan H, Peto R, Henao-Restrepo AM, Presiossi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384:497–511.

58. De Meyer S, Bolkova D, Cinat J, Van Damme E, Buyck C, Van Loock M, et al. Lack of antiviral activity of darunavir against SARS-CoV-2. J Int Infect Dis. 2020;77:10–11.

59. Riva A, Conti F, Bencaccia D, Pezzati L, Sollima S, Merli S, et al. Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res. 2020;157.

60. Eiffy AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020:253.

61. Jockusch S, Tao C, Li X, Anderson TK, Chien M, Kumar S, et al. Triphe- phases of the Two Components in DESCOVY and TRUVADA are Inhibitors of the SARS-CoV-2 Polymerase. bioRxiv. 2020;2020.04.03.022939.

62. Jewell BL, Mudimu E, Stover J, Ten Brink D, Phillips AN, Smith JA, et al. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. Lancet HIV. 2020;7:e629–40.

63. Guo W, Wang HL, Bai H, Liu J, Wei XN, Zhou K, et al. Quick community survey on the impact of COVID-19 outbreak for the healthcare of people living with HIV. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:662–6.

64. Sun S, Hou J, Chen Y, Lu Y, Brown L, Operario D. Challenges to HIV care and psychological health during the COVID-19 pandemic among people living with HIV in China. AIDS Behav. 2020;24:1–2.

65. Pinto RM, Park S. COVID-19 pandemic disrupts HIV continuum of care and prevention: implications for research and practice concerning community-based organizations and frontline providers. AIDS Behav. 2020;24:2486–9.

66. Shuai S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: a syndemic perspective. AIDS Behav. 2020;24:2244–9.

67. Kovalska JD, Skrzat-Klapaczyska A, Bursa D, Balayt T, Begovac J, Chkhartishvili N, et al. HIV care in times of the COVID-19 crisis - where are we now in Central and Eastern Europe? Int J Infect Dis. 2020;92(11):2387–9.

68. Rockwell KL, Gilroy A. Incorporating telemedicine as part of COVID-19 outbreak response systems. AJMC. 2020;26:147–8.

69. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The effectiveness of telemedicine in management of COVID-19 patients in Central and Eastern Europe? Int J Infect Dis. 2020;96:311–4.

70. Klein E, et al. Outcomes among HIV-positive patients hospitalized with COVID-19 in New York City. J Med Virol. 2020;92(11):2387–9.

71. Spring Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.